Key result
Contemporary Lp(a)-targeted trials publicly identified core setting and geography in 100% (14/14) of trials, while clinical context varied from 21.4% (LDL-C) to 92.9% (Lp(a) units).
Why the study?
The amount of publicly available trial-design and clinical-context information varies across development stages of direct Lp(a)-lowering cardiovascular outcome trials.
Cross-Sectional (n=14)
Answers are grounded in this paper and cite their sources.
This cross-sectional meta-research audit establishes a reproducible baseline showing that while broad trial identity and setting are consistently available in public records of contemporary Lp(a)-targeted trials, specific clinical-context details (such as LDL-C optimization and comorbidity criteria) are less frequently retrievable prior to study publication.
Background Direct lipoprotein(a) [Lp(a)]-lowering therapies are advancing toward cardiovascular outcomes testing, but the amount of publicly available trial-design and clinical-context information varies across development stages. Objective To characterize contemporary patient-enrolling direct Lp(a)-targeted pharmacologic trials and describe fixed-date public availability of predefined trial information. Methods We conducted a cross-sectional meta-research study anchored in ClinicalTrials.gov with linked public protocols, statistical analysis plans, design/baseline reports, supplements, and peer-reviewed manuscripts available through May 2, 2026. Contemporary trials started on or after January 1, 2017. Two reviewers independently abstracted 12 prespecified public-information elements. Elements were classified as publicly identified or not publicly identified; no composite score or trial ranking was used. Results Fourteen trials met inclusion criteria, representing 5 agents, 3 therapeutic platforms, and 56,983 planned or reported participants. Seven trials had Lp(a) biomarker primary endpoints, 5 had clinical cardiovascular outcomes, 1 assessed apheresis burden, and 1 assessed calcific aortic valve stenosis progression. Seven trials were published/protocol-supported and 7 registry-only. Cardiovascular/risk phenotype, prevention or special-population setting, and geographic scope were identified in all trials. Other elements were identifiable less consistently: Lp(a) unit (13/14), background lipid-lowering therapy (9/14), numeric Lp(a) threshold (8/14), PCSK9/inclisiran handling (8/14), demographic information (8/14), CKD/eGFR criteria (6/14), heart failure criteria (6/14), diabetes criteria (5/14), and LDL-C context (3/14). Conclusions Public availability varied across contemporary Lp(a)-targeted trials at the data lock, particularly for registry-only programs. These findings describe fixed-date public retrievability and should not be interpreted as protocol deficiency, registry noncompliance, trial quality, efficacy, safety, or regulatory readiness.
No takes yet. Share an insight, caveat, or question.
Tan et al. (2026) conducted a cross-sectional in Elevated lipoprotein(a) [Lp(a)] in contemporary cardiovascular trials (n=14). Direct Lp(a)-targeted pharmacologic trials (pelacarsen, olpasiran, lepodisiran, zerlasiran, muvalaplin) was evaluated on Fixed-date public availability of 12 predefined trial-design and clinical-context information elements. Contemporary Lp(a)-targeted trials publicly identified core setting and geography in 100% (14/14) of trials, while clinical context varied from 21.4% (LDL-C) to 92.9% (Lp(a) units).
Synapse has enriched 10 related papers. Consider them for comparative context: